Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, is developing its proprietary pre|CISION® peptide drug conjugate platform to expand the reach of highly potent cancer therapies. Its pipeline includes the Gen One candidate AVA6000 and the Gen Two sustained-release candidate AVA6103, both designed to deliver chemotherapy payloads directly to tumors while reducing systemic exposure and toxicity.
The company announced that CEO Christina Coughlin has been named one of In Vivo’s 2026 Rising Leaders, recognizing her as a prominent innovator in the life sciences sector. Avacta’s chairman highlighted Coughlin’s rapid progress in advancing the pre|CISION® platform, including moving AVA6103 from discovery to first-in-human Phase 1a dosing within 24 months, underscoring the company’s execution capabilities and growing profile in oncology drug development.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage biopharmaceutical company focused on oncology. It is developing its proprietary pre|CISION® tumor-activated delivery platform, which uses a fibroblast activation protein-based mechanism to concentrate highly potent payloads in the tumor microenvironment while sparing healthy tissue.
The company’s lead program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin designed to deliver chemotherapy directly to tumors with limited peripheral exposure. Avacta is also advancing AVA6103, a Gen Two pre|CISION® candidate employing a sustained-release mechanism to maintain high intratumoral drug levels while minimizing systemic toxicity in cancers with significant unmet needs.
Average Trading Volume: 1,829,245
Technical Sentiment Signal: Buy
Current Market Cap: £306.2M
See more data about AVCT stock on TipRanks’ Stock Analysis page.